British Journal of Clinical Pharmacology reviewed several articles related to CBD modulation of tumorigenesis in several types of cancer. The cancers reviewed included breast cancer, glioma, leukemia, lymphoma, lung cancer, endocrine tumors and angiogenesis. The published article review in 2013 demonstrated the potential effect of CBD as an inhibitor of cancer growth and spread in vitro. With its low toxicity profile and summary of potential anti-tumor benefits, consideration of CBD as an adjunct to standard cancer therapy is a possibility.

Cannabidiol as a Potential Anticancer Drug – British Journal of Pharmacology February 2013